Galangin Enhances Anticancer Efficacy of 5-Fluorouracil in Esophageal Cancer Cells and Xenografts Through NLR Family Pyrin Domain Containing 3 (NLRP3) Downregulation

Cong Zhang; Cui-Lian Luo; Guan-Sheng Shang; De-Xiong Jiang; Qi Song

doi:10.12659/MSM.931630

17 December 2021: Animal Study

Galangin Enhances Anticancer Efficacy of 5-Fluorouracil in Esophageal Cancer Cells and Xenografts Through NLR Family Pyrin Domain Containing 3 (NLRP3) Downregulation

Cong Zhang ^1ABF* , Cui-Lian Luo ^1BCD* , Guan-Sheng Shang ^1DE , De-Xiong Jiang ^1BF , Qi Song ^2AG*

DOI: 10.12659/MSM.931630

Med Sci Monit 2021; 27:e931630

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

View HTML version

Figure 6 Galangin attenuated the malignant growth of esophageal cancer cells in mice. (A, B) Tumor volumes and representative esophageal tissues after resection in mouse xenograft models. (C) Galangin plus fluorouracil (5-FU) inhibited tumor NLR family pyrin domain containing 3 (NLRP3) expression by immunohistology stain assays. Scale bar, 100 μm.

Back to the Article

Galangin Enhances Anticancer Efficacy of 5-Fluorouracil in Esophageal Cancer Cells and Xenografts Through NLR Family Pyrin Domain Containing 3 (NLRP3) Downregulation

Your Privacy